BNC-210
As of the edition of 20 October 2026, BNC-210 is a drug: in active development; acts on CHRNA7.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2024
- Kind
- Unknown
- Registered trials
- 5, 0 stopped early
- Disease areas
- Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRNA7 | Neuronal acetylcholine receptor subunit alpha-7 | P36544 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 4 | 4 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bionomics | Lead sponsor of trials | 2016 to now |